Ask AI
MF Treatment Tool
Expert Guidance for the Selection of Systemic Agents in Myelofibrosis

Released: October 30, 2026

References

Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200-1228.


Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098-4103.


Fedratinib [prescribing information]. Summit, NJ: Celgene Corporation; 2025.


Koschmieder S, Bose P, Ellis MH, et al. Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group. Leukemia. 2024;38:1831-1838.


Kröger N, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2024;11:e62-e74.


Marchetti M, Vannucchi AM, Mascarenhas JO, et al. European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis. Blood Cancer J. 2025;15:207.


Mughal TI, Vaddi K, Sarlis NJ, et al. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89-101.


Pacritinib [prescribing information]. San Diego, CA: CTI BioPharma Corp; 2026.


Palmer J, Scherber R, Girardo M, et al. Patient perspectives regarding allogeneic bone marrow transplantation in myelofibrosis. Biol Blood Marrow Transplant.2019;25(2):398-402.


Ruxolitinib [prescribing information]. Wilmington, DE: Incyte Corporation; 2026.


Shahin OA, Chifotides HT, Bose P, et al. Accelerated phase of myeloproliferative neoplasms. Acta Haematol.2021;144:484-499.


Stein BL, Abdallah M, Abel GA, et al. American Society of Hematology 2026 Guidelines for the Management of Myelofibrosis in Adults. Blood Adv. 2026.


Tefferi A, Alkhateeb H, Gangat N. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. Blood Cancer J. 2023;13:108.


Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: IWG-MRT and ELN consensus report. Blood. 2013;122:1395-1398.


Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769-1770.


Thiele J, Kvasnicka HM, Orazi A, et al. The international consensus classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms. Am J Hematol. 2023;98:166-179.


Yogarajah M, Tefferi A. Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome. Mayo Clin Proc.2017;92:1118-1128.

Access to and use of the Interactive Decision Support Tool titled “Expert Guidance for Systemic Therapy in Myelofibrosis” are subject to the following terms and conditions.

Please read these terms carefully.

This tool educates healthcare professionals about management options for patients with MF. The recommendations reflect the individual expert guidance of John Mascarenhas, MD; Abdulraheem Yacoub, MD; Brady L. Stein, MD, MHS; Kristen Pettit, MD; and Raajit Rampal, MD, PhD. They do not establish a single preferred regimen or a panel consensus.


Materials published by Decera Clinical Education reflect the views of the authors or reviewers, rather than necessarily those of the educational provider or grant supporters. The activity may discuss uses or doses that are not approved by the FDA. Healthcare professionals should review the full current prescribing information, available evidence, and patient-specific factors before treatment.


Although this tool has been developed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of the information, individually or in aggregate. Decera Clinical Education provides this information on an as-is basis. All warranties, including merchantability, fitness for a particular purpose, freedom from computer viruses, and noninfringement of proprietary rights, are disclaimed.


Any trademarks are the property of their respective companies.

© 2026 Decera Clinical Education. All rights reserved.

Program Content